FR2714057B1
(fr)
*
|
1993-12-17 |
1996-03-08 |
Sanofi Elf |
Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
|
FR2741621B1
(fr)
*
|
1995-11-23 |
1998-02-13 |
Sanofi Sa |
Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
|
FR2742148B1
(fr)
*
|
1995-12-08 |
1999-10-22 |
Sanofi Sa |
Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
|
FR2758723B1
(fr)
*
|
1997-01-28 |
1999-04-23 |
Sanofi Sa |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
FR2761266B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
|
FR2761265B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
|
JP2002512188A
(ja)
|
1998-04-21 |
2002-04-23 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ レプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抗酸化剤及び神経保護剤としてのカンナビノイド類
|
JP3852644B2
(ja)
|
1998-09-21 |
2006-12-06 |
チッソ株式会社 |
分割型複合繊維、これを用いた不織布及び吸収性物品
|
FR2789079B3
(fr)
*
|
1999-02-01 |
2001-03-02 |
Sanofi Synthelabo |
Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
|
FR2799124B1
(fr)
*
|
1999-10-01 |
2004-08-13 |
Sanofi Synthelabo |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
US7393842B2
(en)
*
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
FR2800372B1
(fr)
*
|
1999-11-03 |
2001-12-07 |
Sanofi Synthelabo |
Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
|
FR2804604B1
(fr)
|
2000-02-09 |
2005-05-27 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
|
EP1254115A2
(de)
|
2000-02-11 |
2002-11-06 |
Bristol-Myers Squibb Company |
Cannabinoid-rezeptor modulatoren, verfahren zu ihrer herstellung, und verwendung der cannabinoid-rezeptor modulatoren um respiratorische und nicht respiratorische krankheiten zu behandeln
|
FR2809621B1
(fr)
*
|
2000-05-12 |
2002-09-06 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
|
FR2814678B1
(fr)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
US8449908B2
(en)
|
2000-12-22 |
2013-05-28 |
Alltranz, Llc |
Transdermal delivery of cannabidiol
|
AU2002319627A1
(en)
|
2001-07-20 |
2003-03-03 |
Merck And Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
FR2831883B1
(fr)
*
|
2001-11-08 |
2004-07-23 |
Sanofi Synthelabo |
Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
SE0104330D0
(sv)
*
|
2001-12-19 |
2001-12-19 |
Astrazeneca Ab |
Therapeutic agents
|
US7423067B2
(en)
|
2002-03-26 |
2008-09-09 |
Merck & Co., Inc. |
Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
|
FR2837706A1
(fr)
*
|
2002-03-28 |
2003-10-03 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
|
CA2481313A1
(en)
|
2002-04-12 |
2003-10-23 |
Merck & Co., Inc. |
Bicyclic amides
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
NZ537003A
(en)
|
2002-07-18 |
2008-03-28 |
Cytos Biotechnology Ag |
Hapten-carrier conjugates comprising virus like particles and uses thereof
|
US7402835B2
(en)
|
2002-07-18 |
2008-07-22 |
Chevron U.S.A. Inc. |
Heteroatom-containing diamondoid transistors
|
ES2301833T3
(es)
|
2002-07-29 |
2008-07-01 |
Hoffmann La Roche |
Derivados de benzodioxol.
|
EP1546115A4
(de)
|
2002-09-27 |
2010-08-04 |
Merck Sharp & Dohme |
Substituierte pyrimidine
|
GB0228417D0
(en)
*
|
2002-12-05 |
2003-01-08 |
Cancer Rec Tech Ltd |
Pyrazole compounds
|
EP1583742B1
(de)
|
2003-01-02 |
2009-12-02 |
F. Hoffmann-La Roche Ag |
Cb 1 rezeptor inversagonisten
|
KR100674769B1
(ko)
|
2003-01-02 |
2007-02-28 |
에프. 호프만-라 로슈 아게 |
신규 씨비 1 수용체 역작용제
|
TW200505902A
(en)
*
|
2003-03-20 |
2005-02-16 |
Schering Corp |
Cannabinoid receptor ligands
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
US20060135523A1
(en)
*
|
2003-06-18 |
2006-06-22 |
Astrazeneca Ab |
2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
|
GB0314049D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
KR100809201B1
(ko)
|
2003-06-20 |
2008-02-29 |
에프. 호프만-라 로슈 아게 |
카나바노이드 수용체 1 역작용제로서 2-아미노벤조티아졸
|
GB0327331D0
(en)
*
|
2003-11-25 |
2003-12-31 |
Astrazeneca Ab |
Therapeutic agents
|
ES2298840T3
(es)
|
2003-12-08 |
2008-05-16 |
F. Hoffmann-La Roche Ag |
Derivados de tiazol.
|
FR2864958B1
(fr)
*
|
2004-01-12 |
2006-02-24 |
Sanofi Synthelabo |
Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
|
EP1574211A1
(de)
|
2004-03-09 |
2005-09-14 |
Inserm |
Verwendung von CB1-Rezeptor-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankungen
|
CN1950361A
(zh)
|
2004-05-10 |
2007-04-18 |
霍夫曼-拉罗奇有限公司 |
用于治疗肥胖的吡咯或咪唑酰胺化合物
|
ITMI20041032A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
ITMI20041033A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
NZ580387A
(en)
|
2004-07-12 |
2011-06-30 |
Cadila Healthcare Ltd |
Tricyclic pyrazole derivatives as cannabinoid receptor modulators
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
FR2873372B1
(fr)
|
2004-07-22 |
2006-09-08 |
Sanofi Synthelabo |
Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
|
FR2874012B1
(fr)
*
|
2004-08-09 |
2008-08-22 |
Sanofi Synthelabo |
Derives de pyrrole, leur preparation et leur utlisation en therapeutique
|
BRPI0517369A
(pt)
|
2004-10-27 |
2008-10-07 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
|
BRPI0518241A
(pt)
|
2004-11-01 |
2008-04-22 |
Amylin Pharmaceuticals Inc |
métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP1812418B1
(de)
|
2004-11-09 |
2010-10-27 |
F. Hoffmann-La Roche AG |
Dibenzosuberon-derivate
|
WO2006051704A1
(ja)
*
|
2004-11-15 |
2006-05-18 |
Taisho Pharmaceutical Co., Ltd. |
イミン化合物
|
FR2880023B1
(fr)
|
2004-12-23 |
2007-02-23 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
|
EP1844017A1
(de)
*
|
2005-01-06 |
2007-10-17 |
Cadila Healthcare Ltd. |
Amorphe und drei kristalline formen von rimonabanthydrochlorid
|
US8853205B2
(en)
|
2005-01-10 |
2014-10-07 |
University Of Connecticut |
Heteropyrrole analogs acting on cannabinoid receptors
|
US8084451B2
(en)
*
|
2005-01-10 |
2011-12-27 |
University Of Connecticut |
Heteropyrrole analogs acting on cannabinoid receptors
|
FR2881744B1
(fr)
|
2005-02-09 |
2007-04-27 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
|
FR2882263B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
FR2882262B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
DE102005011050A1
(de)
|
2005-03-10 |
2006-09-21 |
Degussa Ag |
Verfahren zur Herstellung von 1-Aminopiperidinderivaten
|
MX2007012213A
(es)
|
2005-04-06 |
2007-12-10 |
Hoffmann La Roche |
Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
|
CN1310891C
(zh)
*
|
2005-05-19 |
2007-04-18 |
金鑫 |
N-哌啶基-1-(2,4-二氯苯基)-4-甲基-5-(4-氯苯基)吡唑-3-甲酰胺有机酸盐及其药物组合物
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
BRPI0613505A2
(pt)
|
2005-06-30 |
2011-01-11 |
Prosidion Ltd |
agonistas de gpcr
|
FR2888236B1
(fr)
*
|
2005-07-08 |
2007-09-21 |
Sanofi Aventis Sa |
Derives de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique
|
EP1743637A1
(de)
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
Verwendung substituierter Pyrazolinderivate und Kombinationen davon zur Behandlung des metabolischen Syndroms
|
GB0514739D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Astrazeneca Ab |
Therapeutic agents
|
EP1752149A1
(de)
|
2005-07-29 |
2007-02-14 |
Laboratorios Del Dr. Esteve, S.A. |
CB1 Antagonists oder umgekehrte Agonists als therapeutische Mittel zur Behandlung der Entzündung mit einbeziehenden Genausdruck
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
AU2006279680B2
(en)
|
2005-08-11 |
2012-12-06 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
AU2006297443B2
(en)
|
2005-09-29 |
2010-08-12 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
JP5069894B2
(ja)
*
|
2005-10-21 |
2012-11-07 |
田辺三菱製薬株式会社 |
ピラゾール化合物
|
CN100999517B
(zh)
*
|
2006-01-11 |
2010-12-15 |
北京摩力克科技有限公司 |
吡唑甲酰胺衍生物,药物组合物和其制备方法
|
EP1816125A1
(de)
*
|
2006-02-02 |
2007-08-08 |
Ranbaxy Laboratories, Ltd. |
Kristalline Formen eines CB1-Cannabinoidrezeptorantagonisten und deren Herstellungsverfahren
|
FR2897060B1
(fr)
*
|
2006-02-08 |
2008-07-25 |
Sanofi Aventis Sa |
Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
CN101062919B
(zh)
*
|
2006-04-26 |
2012-08-15 |
中国人民解放军军事医学科学院毒物药物研究所 |
4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
|
WO2007121687A1
(fr)
*
|
2006-04-26 |
2007-11-01 |
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China |
Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
|
FR2902008A1
(fr)
*
|
2006-06-07 |
2007-12-14 |
Sanofi Aventis Sa |
Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
WO2008038143A2
(en)
*
|
2006-06-22 |
2008-04-03 |
Medichem, S.A. |
Novel solid forms of rimonabant and synthetic processes for their preparation
|
DE602007003024D1
(de)
|
2006-06-27 |
2009-12-10 |
Sandoz Ag |
Neues verfahren zur salzherstellung
|
US7297710B1
(en)
|
2006-07-12 |
2007-11-20 |
Sanofi-Aventis |
Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
|
BRPI0715160A2
(pt)
|
2006-08-08 |
2013-06-11 |
Sanofi Aventis |
imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
|
EP2057144A4
(de)
*
|
2006-09-01 |
2010-06-02 |
Hetero Drugs Ltd |
Neue polymorphe aus rimonabant
|
US7781593B2
(en)
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
WO2008035023A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Cipla Limited |
Polymorphs of rimonabant
|
EP2083831B1
(de)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Verfahren zur behandlung von fettsäure-synthese-hemmern
|
WO2008056377A2
(en)
*
|
2006-11-06 |
2008-05-15 |
Cadila Healthcare Limited |
Polymorphic forms of rimonabant
|
FR2909090B1
(fr)
|
2006-11-23 |
2009-01-09 |
Sanofi Aventis Sa |
Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
|
CZ300115B6
(cs)
*
|
2006-12-01 |
2009-02-11 |
Zentiva, A. S. |
Zpusob výroby N-piperidino-5-(4-chlorfenyl)-1-(2,4-dichlorfenyl)-4-methylpyrazol-3-karboxamidu (rimonabantu)
|
WO2008064615A2
(en)
*
|
2006-12-01 |
2008-06-05 |
Zentiva, A.S. |
Crystalline and amorphous forms of rimonabant and processes for obtaining them
|
AR064736A1
(es)
|
2007-01-04 |
2009-04-22 |
Prosidion Ltd |
Agonistas de gpcr
|
DK2114933T3
(da)
|
2007-01-04 |
2012-01-02 |
Prosidion Ltd |
Piperidin-GPCR-agonister
|
GB0700122D0
(en)
|
2007-01-04 |
2007-02-14 |
Prosidion Ltd |
GPCR agonists
|
WO2008081208A1
(en)
|
2007-01-04 |
2008-07-10 |
Prosidion Limited |
Piperidine gpcr agonists
|
AR064735A1
(es)
|
2007-01-04 |
2009-04-22 |
Prosidion Ltd |
Agonistas de gpcr y composicion farmaceutica en base al compuesto
|
US20080182877A1
(en)
*
|
2007-01-05 |
2008-07-31 |
Westheim Raymond J H |
Rimonabant forms and methods of making the same
|
FR2911136B1
(fr)
|
2007-01-05 |
2009-02-20 |
Sanofi Aventis Sa |
Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
|
EP1944297A1
(de)
*
|
2007-01-09 |
2008-07-16 |
Miklós Vértessy |
Festes und kristallines Rimonabant, Herstellungsverfahren dafür und pharmazeutische Zusammensetzung davon
|
EP1953144A1
(de)
*
|
2007-01-30 |
2008-08-06 |
Sandoz AG |
Polymorphe Formen von N-Piperidin-5-(4-chlorphenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolcarboxamid
|
WO2008102367A1
(en)
*
|
2007-02-19 |
2008-08-28 |
Darmesh Mahendrabhai Shah |
Process for preparation of pyrazole derivatives
|
WO2008101860A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Sandoz Ag |
Novel process for the preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)pyrazole-3-carboxamide
|
FR2913018A1
(fr)
*
|
2007-02-23 |
2008-08-29 |
Sanofi Aventis Sa |
Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
JP4994295B2
(ja)
*
|
2007-04-20 |
2012-08-08 |
田辺三菱製薬株式会社 |
医薬組成物
|
CN101302200B
(zh)
*
|
2007-05-09 |
2011-04-20 |
上海医药工业研究院 |
制备n-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺的方法
|
FR2919184A1
(fr)
*
|
2007-07-26 |
2009-01-30 |
Sanofi Aventis Sa |
L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
|
FR2919866A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de methanol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919863A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919864A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919861A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919868A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de n,n-dimethyformamide de rimonabant, et son procede de preparation
|
FR2919865A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919867A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
|
FR2919862A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
GB0720389D0
(en)
|
2007-10-18 |
2008-11-12 |
Prosidion Ltd |
G-Protein Coupled Receptor Agonists
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
DE102007063671A1
(de)
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
WO2009109222A1
(en)
*
|
2008-03-04 |
2009-09-11 |
Maprimed, S. A. |
Process for the preparation of rimonabant
|
WO2009153804A1
(en)
*
|
2008-06-16 |
2009-12-23 |
Cadila Healthcare Limited |
Process for preparing form i of rimonabant
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
US10053444B2
(en)
|
2009-02-19 |
2018-08-21 |
University Of Connecticut |
Cannabinergic nitrate esters and related analogs
|
EP2470552B1
(de)
|
2009-08-26 |
2013-11-13 |
Sanofi |
Neuartige kristalline heteroaromatische Fluorglycosidhydrate, Pharmazeutika, die diese Verbindungen umfassen, und deren Verwendung
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120057A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
CN102206182B
(zh)
*
|
2011-04-11 |
2013-03-13 |
中国药科大学 |
盐酸利莫那班的合成方法
|
AR087701A1
(es)
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
EP2567959B1
(de)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
|
AU2012316331B2
(en)
*
|
2011-09-30 |
2016-02-25 |
National Health Research Institutes |
Pyrazole compounds
|
AU2015269247B2
(en)
|
2014-06-06 |
2019-10-24 |
Research Triangle Institute |
Apelin receptor (APJ) agonists and uses thereof
|
JP2019501899A
(ja)
*
|
2015-12-09 |
2019-01-24 |
リサーチ トライアングル インスティテュート |
改良アペリンレセプター(apj)アゴニストおよびその使用
|
CA3125847A1
(en)
|
2020-07-27 |
2022-01-27 |
Makscientific, Llc |
Process for making biologically active compounds and intermediates thereof
|
US12054480B2
(en)
|
2020-07-31 |
2024-08-06 |
Makscientific, Llc |
Compounds for treating cannabinoid toxicity and acute cannabinoid overdose
|
PT4000621T
(pt)
|
2020-11-18 |
2023-07-07 |
Fundacion Del Hospital Nac De Paraplejicos Para La Investigacion Y La Integracion |
Utilização de antagonistas e/ou agonistas inversos de recetores cb1 para preparar medicamentos para tratar síndrome de fadiga pós-viral
|